Technology News and Research

RSS

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia's first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world's 850th recipient of the Total Artificial Heart.

9 Apr 2010

Savings from computerized medical records are hard to measure

Kaiser Health News staff writer Christopher Weaver writes: "When it comes to health policy, few ideas find as much bipartisan support as the notion that widespread adoption of health information technology could improve medical care and save money.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

QuadraMed introduces Quantim ICD-10 Coding Simulator

QuadraMed® Corporation, a leading provider of healthcare technologies and services that help turn quality care into positive financial outcomes, today announced the general availability of the industry's first ICD-10 Simulator developed to help coders prepare for the transition to ICD-10. The Quantim ICD-10 Coding Simulator, which is available today as a component of the ICD-10 Countdown Program, is a unique solution that duplicates the ICD-10 coding environment for accelerated training and practice purposes.

9 Apr 2010

Merge Healthcare to exhibit expanded suite of women's imaging solutions at NCBC 2010

Merge Healthcare, a health IT solutions leader, today announced it will be showcasing it's expanded suite of innovative solutions and support of comprehensive continuing education programs for the advancement of women's imaging at the National Conference on Breast Cancer (NCBC) 2010. Additionally, Merge plans to introduce and collaborate with attendees on its Women's Healthcare Initiative, which builds partnerships with clinicians to provide broader access to training in the analysis and interpretation of these important studies.

8 Apr 2010

First Edition: April 8, 2010

Today's health policy news coverage explores the political and policy implications of the new health reform law.

8 Apr 2010

BeaconEquity.com releases investment report on PURE

BeaconEquity.com announces an investment report featuring PURE Bioscience. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

8 Apr 2010

Health Affairs report shows value of patient-centered IT at Group Health

Hopes are high that health information technology will support care between office visits, boost efficiency and convenience, and help patients lead healthier lives. An evaluation in the April Health Affairs suggests how to make the most of this new approach: Routinely ask patients how they like it and what they want.

8 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Molecular gauge helps examine working of new drugs when they bind to DNA or RNA

Luminescent markers are an indispensable tool for researchers working with DNA. But the markers are troublesome. Some tend to destroy the function and structure of DNA when inserted. Others emit so little light, that they can barely be detected in the hereditary material. So researchers have been asking for alternative markers.

8 Apr 2010

Hospital TV remotes are potential reservoir of bacteria

According to RID (Committee to Reduce Infection Deaths) over thirty billion dollars is spent each year in the US on hospital-acquired infections. (Infections caught while hospitalized). These very preventable infections cost an additional $15,000.00 on average per patient infected and kill more people in this country than AIDS, breast cancer and car accidents combined.

8 Apr 2010

LensAR receives patent for using laser technology to increase flexibility of ocular lens

LensAR, Inc., the leading developer of next generation laser technology for cataract surgery and presbyopia, today announced the issuance of United States patent 7,655,002. This patent addresses methods for using laser technology to increase the flexibility of the ocular lens in order to both restore accommodation in presbyopia patients and allow easier removal of hardened lenses in cataract patients.

8 Apr 2010

UTHealth awarded $15.3M for establishing HIT REC

The U.S. Department of Health and Human Services announced today that The University of Texas Health Science Center at Houston (UTHealth) has been awarded $15.3 million to establish a Health Information Technology Regional Extension Center (REC).

8 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

Biocartis closes Series 'B' equity financing round

Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD 41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.

From Biocartis 8 Apr 2010

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Saint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor Center in an effort to speed up the time between diagnosis and treatment.

8 Apr 2010

Single vaccine for anthrax and plague: iBio confirms grant of rights

iBio, Inc. confirmed today the grant of rights to use iBio's proprietary technology, the iBioLaunch™ platform, in support of a $5.3 million government-funded project for the development of a single vaccine to protect against both anthrax and plague. The project will be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology.

8 Apr 2010

Sigma-Aldrich, Boehringer Ingelheim Pharma enter distribution agreement for RESOMER polymers

Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.

8 Apr 2010

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical and medical device company, today announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada's Bankruptcy and Insolvency Act and Chapter 11 of the United States Bankruptcy Code.

8 Apr 2010

Unique collaboration in fetal medicine among Columbus' healthcare professionals

The Columbus Fetal Medicine Collaborative has been formed by Mount Carmel Health System, OhioHealth, The Ohio State University Medical Center and Nationwide Children's Hospital joining together to provide optimal outcomes for high-risk expectant mothers and their babies with suspected fetal abnormalities.

8 Apr 2010

Technology News and Research

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

Savings from computerized medical records are hard to measure

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

QuadraMed introduces Quantim ICD-10 Coding Simulator

Merge Healthcare to exhibit expanded suite of women's imaging solutions at NCBC 2010

First Edition: April 8, 2010

BeaconEquity.com releases investment report on PURE

Health Affairs report shows value of patient-centered IT at Group Health

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Molecular gauge helps examine working of new drugs when they bind to DNA or RNA

Hospital TV remotes are potential reservoir of bacteria

LensAR receives patent for using laser technology to increase flexibility of ocular lens

UTHealth awarded $15.3M for establishing HIT REC

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Biocartis closes Series 'B' equity financing round

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Single vaccine for anthrax and plague: iBio confirms grant of rights

Sigma-Aldrich, Boehringer Ingelheim Pharma enter distribution agreement for RESOMER polymers

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Unique collaboration in fetal medicine among Columbus' healthcare professionals

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News